Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 201-210 of 225 for multiple myeloma

Edit search filters
  1. Sarcopenia Impact Among Older Patients With Newly Diagnosed Multiple Myeloma

    Rochester, MN

  2. Perceived Financial Hardship in Patients with Multiple Myeloma and Their Caregivers

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  3. MMRF Molecular Profiling Protocol

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  4. American Society of Hematology Research Collaborative’s Data Hub Multiple Myeloma Program

    Rochester, MN

  5. The Impact of a Geriatric Assessment in Elderly Patients with Multiple Myeloma

    Rochester, MN

  6. A Study to Compare Dual-Energy CT and Whole Body MRI for Monitoring of Bone Involvement in Multiple Myeloma Patients

    Rochester, MN

  7. A Study to Evaluate Effectiveness and Quality of Life Outcomes of Daratumumab in Relapsed/Refractory Multiple Myeloma Patients

    Rochester, MN

  8. Manufacturing Outcomes with Patient Factors from Multiple Myeloma Patients Prescribed Ciltacabtagene Autoleucel

    Rochester, MN

  9. Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)

    Rochester, MN

  10. Myeloma Referral Study (Race, Ethnicity, and Familial Etiologic Relationship, Risk Association, and Linkage Study)

    Rochester, MN

.

Mayo Clinic Footer